Is ruxolitinib phosphate tablets/ruxolitinib a chemotherapy drug?

Ruxolitinib is a tyrosine kinase inhibitor that targets the Janus kinase (JAK) and signal transducer and activator of transcription (STAT) pathways. This drug inhibits the growth and spread of abnormal cells by inhibiting the activity of tyrosine kinases in the body. Ruxolitinib tablets can be used to treat myelofibrosis, polycythemia vera, and steroid-refractory graft-versus-host disease in allogeneic stem cell transplantation.

Chemotherapy drugs usually refer to chemical drugs. Most of these drugs are active ingredients extracted from natural minerals, animals and plants, and are chemically synthesized. They mainly treat cancer by directly killing cancer cells or preventing their growth. Although ruxolitinib is an anti-tumor drug, it does not work by directly killing cancer cells. Its main mechanism of action is to selectively inhibit the activity of JAK3 and Tyk2 proteins, and has a signal transduction effect on many important cytokines and growth factors related to hematopoiesis and immune function. Therefore, ruxolitinib is not a chemotherapy drug in the traditional sense.

The medical application of ruxolitinib is mainly for patients with intermediate-risk or high-risk myelofibrosis (MF), polycythemia vera (PV) and steroid-refractory graft-versus-host disease (GVHD). It is mainly used to treat splenomegaly or symptoms related to these diseases. Although ruxolitinib is not a chemotherapy drug, it may still cause some adverse reactions, such as anemia, fatigue, etc.

Therefore, when using ruxolitinib, patients should follow their doctor's instructions and monitor changes in their condition and possible side effects. At the same time, maintain good living habits and avoid overexertion and mood swings to facilitate physical recovery.